aSection of Nephrology and Hypertension, Louisiana State University Health Science Center, New Orleans, Louisiana
bDivision of Nephrology/Hypertension, Mayo Clinic, Rochester, Minnesota
cCoordinating Center for Clinical Trials, The University of Texas School of Public Health, Houston, Texas
dDivision of Endocrinology, Kaiser Permanente of Georgia and Emory University School of Medicine, Atlanta, Georgia
eThe National Heart, Lung, and Blood Institute, Bethesda, Maryland
fCenter for Human Genetics, Marshfield Clinic Research Foundation, Marshfield, Wisconsin
gHoward University Hypertension and Lipid Clinic, Howard University Hospital, Washington, District of Columbia
hVeterans Affairs Medical Center and Wright State University Veterans Affairs Campus, Dayton, Ohio, USA
Correspondence to José-Miguel Yamal, PhD, Coordinating Center for Clinical Trials, The University of Texas School of Public Health, 1200 Pressler Street, Houston, TX 77030, USA. Tel: +1 713 500 9566; fax: +1 713 500 9530; e-mail: [email protected]
Abbreviations: ACE, angiotensin-converting enzyme; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; BP, blood pressure; CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; ESRD, end-stage renal disease; GFR, glomerular filtration rate; LVH, left-ventricular hypertrophy; MDRD, Modification of Diet in Renal Disease; MI, myocardial infarction
Received 7 October, 2013
Revised 11 March, 2014
Accepted 11 March, 2014
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.jhypertension.com).
